TECP
FTH

Trails Edge Capital Partners’s Faeth Therapeutics FTH Stock Holding History

Trails Edge Capital Partners’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
515,335
+390,335
+312% +$9.03M 2.05% 20
2026
Q1 		$3.94M Buy
+125,000
New +$2.5M 0.9% 26

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Trails Edge Capital Partners's FTH Position: Q2 2026 in Review

Trails Edge Capital Partners increased its Faeth Therapeutics (FTH) stake by 312% in Q2 2026, buying an estimated $9.03M and bringing the position to 515,335 shares worth $12.9M. The position accounts for 2.05% of the portfolio, ranked #20.

Trails Edge Capital Partners first reported a position in FTH in Q1 2026 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Trails Edge Capital Partners held 515,335 shares of Faeth Therapeutics worth $12.9M as of Q2 2026.
  • Trails Edge Capital Partners bought 390,335 Faeth Therapeutics shares in Q2 2026, an estimated $9.03M.
  • Faeth Therapeutics made up 2.05% of Trails Edge Capital Partners's portfolio in Q2 2026, its #20 holding.
  • Trails Edge Capital Partners first reported a position in Faeth Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.